Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
05
2022
accepted:
16
11
2022
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Liver metastases are common in patients with breast cancer, and determining the factors associated with such metastases may improve both their early detection and treatment. Given that liver function protein level changes in these patients have not been determined, the aim of our study was to investigate liver function protein level changes over time, spanning 6 months before the detection of liver metastasis to 12 months after. We retrospectively studied 104 patients with hepatic metastasis from breast cancer who were treated at the Departments of Internal Medicine I and the Department of Obstetrics and Gynecology at the Medical University of Vienna between 1980 and 2019. Data were extracted from patient records. Aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase and alkaline phosphatase were significantly elevated when compared to normal range 6 months before the detection of liver metastases (p<0.001) Albumin was decreased (p<0.001). The values of aspartate aminotransferase, gamma-glutamyltransferase, and lactate dehydrogenase were significantly increased at the time of diagnosis compared to 6 months prior (p<0.001). Patient- and tumor-specific parameters had no influence on these liver function indicators. Elevated aspartate aminotransferase (p = 0.002) and reduced albumin (p = 0.002) levels at the time of diagnosis were associated with shorter overall survival. Liver function protein levels should be considered as potential indicators when screening for liver metastasis in patients with breast cancer. With the new treatment options available, it could lead to prolonged life.
Sections du résumé
BACKGROUND
Liver metastases are common in patients with breast cancer, and determining the factors associated with such metastases may improve both their early detection and treatment. Given that liver function protein level changes in these patients have not been determined, the aim of our study was to investigate liver function protein level changes over time, spanning 6 months before the detection of liver metastasis to 12 months after.
METHODS
We retrospectively studied 104 patients with hepatic metastasis from breast cancer who were treated at the Departments of Internal Medicine I and the Department of Obstetrics and Gynecology at the Medical University of Vienna between 1980 and 2019. Data were extracted from patient records.
RESULTS
Aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase and alkaline phosphatase were significantly elevated when compared to normal range 6 months before the detection of liver metastases (p<0.001) Albumin was decreased (p<0.001). The values of aspartate aminotransferase, gamma-glutamyltransferase, and lactate dehydrogenase were significantly increased at the time of diagnosis compared to 6 months prior (p<0.001). Patient- and tumor-specific parameters had no influence on these liver function indicators. Elevated aspartate aminotransferase (p = 0.002) and reduced albumin (p = 0.002) levels at the time of diagnosis were associated with shorter overall survival.
CONCLUSION
Liver function protein levels should be considered as potential indicators when screening for liver metastasis in patients with breast cancer. With the new treatment options available, it could lead to prolonged life.
Identifiants
pubmed: 36867604
doi: 10.1371/journal.pone.0278454
pii: PONE-D-22-13541
pmc: PMC9983906
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Albumins
0
Aspartate Aminotransferases
EC 2.6.1.1
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0278454Informations de copyright
Copyright: © 2023 Leser et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cancer. 2021 Oct 15;149(8):1520-1528
pubmed: 34013530
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Dig Liver Dis. 2019 Jul;51(7):1030-1035
pubmed: 30686716
Semin Cancer Biol. 2020 Feb;60:14-27
pubmed: 31421262
Curr Treat Options Oncol. 2021 Aug 23;22(10):94
pubmed: 34426881
J Transl Med. 2015 Feb 15;13:64
pubmed: 25885919
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Future Oncol. 2015;11(10):1519-30
pubmed: 25963429
Eur J Cancer. 2003 Nov;39(17):2439-49
pubmed: 14602130
Cancers (Basel). 2021 Jul 27;13(15):
pubmed: 34359677
Transl Cancer Res. 2020 Mar;9(3):1506-1517
pubmed: 35117498
Cancer Treat Rev. 2000 Apr;26(2):91-102
pubmed: 10772967
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
Br J Cancer. 2003 Jul 21;89(2):284-90
pubmed: 12865918
Cancer Biol Med. 2012 Mar;9(1):57-62
pubmed: 23691457
Nat Rev Dis Primers. 2021 Apr 15;7(1):27
pubmed: 33859205
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Eur J Cancer. 1990;26(5):574-7
pubmed: 2144744
Surgery. 2012 May;151(5):710-6
pubmed: 22285778